Cell News and Research

RSS

Cord Blood America to begin sale of DNA Predisposition testing services

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that within 90 days it will begin selling DNA Predisposition testing services in conjunction with The DNA Shop, LLC,Henderson, Nevada.

11 Aug 2010

Common soluble proteins become insoluble and form aggregates while aging: Study

In neurodegenerative diseases, clumps of insoluble proteins appear in patients' brains. These aggregates contain proteins that are unique to each disease, such as amyloid beta in Alzheimer's disease, but they are intertwined with small amounts of many other insoluble proteins that are normally present in a soluble form in healthy young individuals. For years, these other proteins were thought to be accidental inclusions in the aggregates, much as a sea turtle might be caught in a net of fish.Now, in a surprising new finding, researchers at the University of California, San Francisco, report that many of the proteins present as minor components of disease aggregates actually clump together as a normal part of aging in healthy individuals.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Researchers identify perforant path brain passage associated with Alzheimer's disease

With the help of volunteers aged 18 to 89, UC Irvine researchers have identified for the first time in humans a long-hidden part of the brain called the perforant path. Scientists have struggled for decades to locate the tiny passage, which is believed to deteriorate gradually as part of normal aging and far more quickly due to Alzheimer's disease.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

StemCells second-quarter net loss decreases to $4.61 million

StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.

11 Aug 2010

Georgia Institute receives EUREKA grant to design brain tumor treatment

The Georgia Institute of Technology has received a EUREKA grant from the National Institutes of Health (NIH) to design a new way to treat invasive brain tumors by capturing the migrating cells that spread the disease. The EUREKA -- Exceptional, Unconventional Research Enabling Knowledge Acceleration -- program helps scientists test new, unconventional ideas or tackle major methodological or technical challenges.

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

Advanced Cell Diagnostics, Inc., announces the launch and immediate availability of RNAscope™ FFPE Assay Kit, a line of RUO products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded tissue specimens with single molecule sensitivity.

From Advanced Cell Diagnostics 11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Scientists develop new method to enable drug release inside cancer cells

Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.The new system - the first to utilize a class of porous nanomaterials driven by a magnetic core - has the potential to improve both targeted drug-delivery and magnetic resonance imaging in the treatment of cancer and other diseases.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

Atrium awarded 3-year national contract from Premier for surgical mesh products

Atrium Medical Corporation, pioneering advancements in biological, mechanical and therapeutic solutions for soft tissue reinforcement, is proud to announce that the company was awarded a three-year national contract from Premier Purchasing Partners L.P., the group purchasing organization of Premier, Inc. (Charlotte, NC).

10 Aug 2010

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

Africa needs policies, regulations to spur development of innovative mobile phone-based applications

The fast-growing use of cell phones in Africa - where many people lack the basic human necessities - has made headlines worldwide the past few years. The surprising boom has led to widespread speculation that cell phones could potentially transform the impoverished continent.

10 Aug 2010

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.

10 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

UT Southwestern enters partnership with Sun Yat-sen University to promote scientific research

UT Southwestern Medical Center has entered into an academic and scientific partnership with Sun Yat-sen University and its First Affiliated Hospital in Guangzhou, China. The first international institutional affiliation for UT Southwestern and a first step in implementing the global health initiative that is one of the medical center's current strategic priorities, the partnership was developed to promote joint scientific research, educational, and training activities.

10 Aug 2010

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd - Cancer Research UK's commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

10 Aug 2010

Cell News and Research

Cord Blood America to begin sale of DNA Predisposition testing services

Common soluble proteins become insoluble and form aggregates while aging: Study

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Researchers identify perforant path brain passage associated with Alzheimer's disease

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

StemCells second-quarter net loss decreases to $4.61 million

Georgia Institute receives EUREKA grant to design brain tumor treatment

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Scientists develop new method to enable drug release inside cancer cells

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Atrium awarded 3-year national contract from Premier for surgical mesh products

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Africa needs policies, regulations to spur development of innovative mobile phone-based applications

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

UT Southwestern enters partnership with Sun Yat-sen University to promote scientific research

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics